Hagino, Hiroshi http://orcid.org/0000-0001-8053-1095
Yoshinaga, Yoko
Hamaya, Etsuro
Lin, Tzu-Chieh
Ajmera, Mayank
Meyers, Juliana
Funding for this research was provided by:
Amgen
Article History
Received: 11 July 2022
Accepted: 12 December 2022
First Online: 23 January 2023
Declarations
:
: Hiroshi Hagino has received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Pfizer Japan Inc., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Co., Ltd, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Yoko Yoshinaga and Etsuro Hamaya are employees of Amgen K.K., Japan, and Tzu-Chieh Lin is an employee of Amgen, Inc, USA. Mayank Ajmera and Juliana Meyers are full-time employees of RTI Health Solutions, an independent nonprofit research organization retained by Amgen to conduct the research that is the subject of this manuscript. Compensation to Mayank Ajmera and Juliana Meyers is unconnected to the studies on which they worked.